1929582-97-7

Usage

Uses

Used in Pharmaceutical Research:
1-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)-N-methylmethanamine is used as a research compound for studying adenosine receptors and their role in different physiological and pathological processes. Its adenosine A1 receptor antagonist activity makes it a valuable tool in understanding the complex interactions and functions of these receptors in the body.
Used in Drug Development:
In the pharmaceutical industry, 1-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)-N-methylmethanamine is used as a lead compound in the development of new drugs targeting adenosine A1 receptors. Its selective antagonist activity can potentially be harnessed to create therapeutic agents for treating conditions related to the dysregulation of adenosine receptor signaling.
Further research and testing are essential to fully comprehend the chemical and pharmacological properties of 1-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)-N-methylmethanamine and to explore its potential applications in medicine.

Upstream product

• 1148003-33-1 2-chloro-9-methyl-6-morpholino-9H-purine-8-carbaldehyde 
• 1148003-35-3 4-(2-chloro-9-methyl-9H-purin-6-yl)morpholine 
• 4010-81-5 4-(2-chloro-9H-purin-6-yl)morpholine 
• 5451-40-1 2,6-dichloro-7H-purine 

Relevant academic research and scientific papers

Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities

In the present study, a series of novel histone deacetylase (HDAC) inhibitors using the morpholinopurine as the capping group were designed and synthesized. Several compounds demonstrated significant HDAC inhibitory activities and antiproliferative effects against diverse human tumor cell lines. Among them, compound 10o was identified as a potent class I and class IIb HDAC inhibitor with good pharmaceutical profile and druglike properties. Western blot analysis further confirmed that 10o more effectively increased acetylated histone H3 than panobinostat (LBH-589) and vorinostat (SAHA) at the same concentration in vitro. In in vivo efficacy evaluations of HCT116, MV4-11, Ramos, and MM1S xenograft models, 10o showed higher efficacy than SAHA or LBH-589 without causing significant loss of body weight and toxicity. All the results indicated that 10o could be a suitable candidate for treatment of both solid and hematological cancer.